Related Experiment Videos
Aminophylline versus doxapram in idiopathic apnea of prematurity: a double-blind controlled study
Insights
Doxapram and aminophylline showed similar effectiveness for treating idiopathic apnea of prematurity. Adding doxapram to aminophylline significantly reduced apnea in infants unresponsive to aminophylline alone.
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Clinical Pharmacology
Background:
- Idiopathic apnea of prematurity (IAP) is a common respiratory challenge in preterm infants.
- Current treatments like aminophylline have variable efficacy.
- Exploring combination therapies is crucial for improving IAP management.
Purpose of the Study:
- To compare the efficacy of doxapram versus aminophylline as monotherapy for IAP.
- To evaluate the effectiveness of adding doxapram to aminophylline in non-responsive IAP cases.
Main Methods:
- A two-part, double-blind, controlled study design.
- Part 1: Compared doxapram and aminophylline monotherapy.
- Part 2: Assessed the addition of doxapram to aminophylline in infants with persistent apnea.
Main Results:
- No statistically significant difference in apnea cessation between doxapram (8/15) and aminophylline (6/11) in Part 1.
- In Part 2, 8 of 10 infants unresponsive to aminophylline alone showed complete apnea cessation with added doxapram.
- Infants receiving aminophylline plus placebo showed no reduction in apnea frequency.
Conclusions:
- Doxapram and aminophylline demonstrate comparable initial efficacy for IAP.
- Combination therapy with doxapram significantly benefits infants with aminophylline-resistant IAP.
- This suggests a potential role for doxapram as an adjunct therapy in refractory IAP.
Abstract:
A double-blind controlled study, in two parts, was undertaken to compare the effectiveness of aminophylline and doxapram therapy in idiopathic apnea of prematurity. In the first part of this study, eight of 15 infants responded to doxapram therapy with complete cessation of apneic spells and six of 11 infants responded similarly to administration of aminophylline. These differences were statistically insignificant. In the second part of the study, assessment was made of whether the addition of doxapram to aminophylline therapy was effective in treatment of apnea of prematurity that had been unresponsive to aminophylline alone. Of ten infants who continued to have apneic spells during treatment with aminophylline, eight responded to the addition of doxapram with complete cessation of apnea. Nine infants received placebo in addition to aminophylline, and none had a reduction in frequency of apnea.